Intrinsiqq
Prestige Consumer Healthcare Inc. logo

Prestige Consumer Healthcare Inc. Quality Score

PBH

⊜ Compare
Quality48

Growth is the primary weakness (avg 0/100). Valuation is the relative bright spot.

Broad-market heuristics · Not a buy/sell signal

Valuation and growth

Earnings Multiple
90/100
14.9x

Under 20x, reasonable relative to earnings

Cash Flow Multiple
90/100
10.7x

Under 20x cash flow, well covered

Revenue Growth
0/100
-0.7%

Below 2%, essentially flat

Cash Flow Growth
0/100
1.5%

Below 2%, essentially flat

Business Quality & Capital Allocation

Share Dilution
100/100
-4.6%

Shrinking >2%, active buybacks

Margin Trend
100/100
+28.5pp

Expanded 3+pp, strong improvement

Capital Structure
0/100
$1.97B

Net debt/FCF of 8.4x, high leverage

2023
$58.0M
$1.37B
2024
$46.0M
$1.14B
2025
$98.0M
$1.04B
2026
$64.0M
$1.04B
TTM
$89.0M
$2.06B
CashDebt
Return on Capital
0/100
7.2%

Below 8%, may not cover cost of capital

Customize WeightsPremiumUpgrade

Prestige Consumer Healthcare (PBH) quality: score, margins and returns

Prestige Consumer Healthcare (PBH) scores 48/100 on Intrinsiqq's quality score (a mixed business), a weighted blend of 8 metrics each scored 0 to 100, on 26.5% operating margins and 7.2% ROIC. Every metric is computed from SEC filings; this is analysis, not investment advice.

Frequently asked

Is Prestige Consumer Healthcare (PBH) a high-quality business?+

Prestige Consumer Healthcare scores 48 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which rates it a mixed business on these measures. Recent figures include a 26.5% operating margin and a 7.2% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.

What does Prestige Consumer Healthcare's quality score measure?+

Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from PBH's SEC filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where Prestige Consumer Healthcare scores well and where it falls behind.

What is Prestige Consumer Healthcare's return on invested capital (ROIC)?+

Prestige Consumer Healthcare earns about 7.2% on its invested capital, which is modest. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to PBH's margins and growth on this scorecard to judge durability.

How profitable is Prestige Consumer Healthcare?+

Prestige Consumer Healthcare runs an operating margin of about 26.5% and a net margin of about 15.7%. Revenue has grown at roughly 2.7% a year recently. High, stable margins usually point to pricing power and operating discipline. Margins are most telling next to growth and returns on capital, all of which feed this quality score. This is analysis from SEC filings, not investment advice.

How the market compares: US profitability statistics

SourceQuality score computed from the 10-Q filed 31 Jul 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 19 Sept 2026. How this is calculated.

Fiscal year ends Mar. Sector medians are approximate S&P 500 benchmarks and update periodically. Checks use broad-market heuristics, so sector norms may differ, and the valuation checks are more cyclical than the quality checks.

Peers

Pharmaceutical Preparations · Pick stocks to compare with PBH

CompareIntrinsic value
APLSApellis Pharmaceuticals, Inc.
$3.10+3.29%83
ACADAcadia Pharmaceuticals Inc.
$21.49+4.47%74
PTCTPTC Therapeutics, Inc.
$68.97+1.25%65
ANIPAni Pharmaceuticals Inc.
$72.89+0.84%85
HRMYHarmony Biosciences Holdings, Inc.
$34.42-7.04%82
MDGLMadrigal Pharmaceuticals, Inc.
$400.67+1.10%10
IONSIonis Pharmaceuticals, Inc.
$40.15-0.67%39
INDVIndivior Pharmaceuticals, Inc.
$36.28+2.57%80

Held by ETFs

PBH is in 96 US ETFs. The largest of them, with PBH's weight in each:

Spot a number that looks wrong? Check it in PBH's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing PBH

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.